Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athenex Inc ATNXQ

Healthcare Biotechnology
Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is... see more

Recent & Breaking News (GREY:ATNXQ)

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021

GlobeNewswire November 22, 2021

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

GlobeNewswire November 18, 2021

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

GlobeNewswire November 9, 2021

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition

GlobeNewswire November 4, 2021

Athenex Provides Third Quarter 2021 Corporate and Financial Update

GlobeNewswire November 4, 2021

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

GlobeNewswire October 22, 2021

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021

GlobeNewswire October 21, 2021

Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy

GlobeNewswire October 18, 2021

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer

GlobeNewswire October 11, 2021

Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis

GlobeNewswire September 27, 2021

Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021

GlobeNewswire September 16, 2021

Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit

GlobeNewswire September 15, 2021

Athenex Provides Second Quarter 2021 Corporate and Financial Update

GlobeNewswire August 5, 2021

Athenex Announces Additional Licensing Agreements for Tirbanibulin

GlobeNewswire July 26, 2021

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

GlobeNewswire July 22, 2021

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

GlobeNewswire July 19, 2021

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

GlobeNewswire July 6, 2021

SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders

Business Wire June 7, 2021

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

GlobeNewswire June 4, 2021

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

GlobeNewswire May 21, 2021